Sequencing Therapy for Optimal Response in Mirikizumab (STORM)-study: A tertiary referral center study on patients with therapy-refractory ulcerative colitis
Mirikizumab treatment had good short- and long-term efficacy in patients with UC who previously received biologic therapy. In particular, patients with prior anti-TNF therapies had favorable biochemical remission outcomes.
Authors
- Kathrin Sprinzl (ORCID: https://orcid.org/0000-0002-0599-3801)
- Iulia Dahmer
- Florian Alexander Michael (ORCID: https://orcid.org/0000-0002-9305-3691)
- Raul Lande (ORCID: https://orcid.org/0009-0009-4201-0315)
- A Dienethal
- Alica Kubesch (ORCID: https://orcid.org/0000-0002-8627-6088)
- Karima Farrag (ORCID: https://orcid.org/0000-0002-5071-7072)
- K Stratmann-Vollrath
- Irina Blumenstein (ORCID: https://orcid.org/0000-0002-7841-0494)
- S Zeuzem
- Anna Leutgöb
Institutions
- Goethe University Frankfurt (DE)
- University Hospital Frankfurt (DE)
Publication Details
- Journal
- PLoS ONE
- Published
- 2025-10-24
- DOI
- https://doi.org/10.1371/journal.pone.0334897
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00